| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sentinel Lymph Node Biopsy | 35 | 2021 | 1458 | 5.260 |
Why?
|
| Vulvar Neoplasms | 28 | 2021 | 235 | 4.320 |
Why?
|
| Genital Neoplasms, Female | 31 | 2021 | 794 | 3.680 |
Why?
|
| Lymph Nodes | 28 | 2016 | 3078 | 3.150 |
Why?
|
| Uterine Cervical Neoplasms | 56 | 2017 | 1903 | 2.770 |
Why?
|
| Lymph Node Excision | 28 | 2021 | 2062 | 1.510 |
Why?
|
| Lymphatic Metastasis | 38 | 2021 | 4963 | 1.410 |
Why?
|
| Ovarian Neoplasms | 46 | 2020 | 4795 | 1.110 |
Why?
|
| Carcinoma, Squamous Cell | 38 | 2017 | 5593 | 1.100 |
Why?
|
| Endometrial Neoplasms | 16 | 2017 | 1387 | 1.020 |
Why?
|
| Hysterectomy | 14 | 2017 | 654 | 1.010 |
Why?
|
| Sentinel Lymph Node | 4 | 2021 | 235 | 1.000 |
Why?
|
| Neoplasm Recurrence, Local | 40 | 2020 | 10400 | 0.920 |
Why?
|
| Laparoscopy | 12 | 2020 | 1302 | 0.820 |
Why?
|
| Gynecologic Surgical Procedures | 9 | 2019 | 381 | 0.800 |
Why?
|
| Uterine Neoplasms | 10 | 2008 | 576 | 0.790 |
Why?
|
| Female | 191 | 2021 | 149107 | 0.690 |
Why?
|
| Venous Thromboembolism | 3 | 2015 | 376 | 0.660 |
Why?
|
| Fallopian Tube Neoplasms | 9 | 2020 | 155 | 0.620 |
Why?
|
| Pelvic Exenteration | 7 | 2006 | 112 | 0.610 |
Why?
|
| Vaginal Neoplasms | 5 | 2010 | 152 | 0.520 |
Why?
|
| Middle Aged | 131 | 2021 | 90433 | 0.520 |
Why?
|
| Adult | 119 | 2020 | 82090 | 0.510 |
Why?
|
| Humans | 199 | 2021 | 271010 | 0.510 |
Why?
|
| Neoplasm Staging | 45 | 2021 | 14013 | 0.490 |
Why?
|
| Aged | 111 | 2021 | 73460 | 0.490 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 35 | 2020 | 16689 | 0.490 |
Why?
|
| Neoplasm Seeding | 2 | 2004 | 66 | 0.460 |
Why?
|
| Groin | 7 | 2012 | 78 | 0.450 |
Why?
|
| Peritoneal Neoplasms | 11 | 2014 | 859 | 0.440 |
Why?
|
| Pelvis | 9 | 2017 | 381 | 0.430 |
Why?
|
| Prescription Fees | 1 | 2012 | 17 | 0.410 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2012 | 62 | 0.410 |
Why?
|
| Rosaniline Dyes | 4 | 2004 | 109 | 0.410 |
Why?
|
| Radionuclide Imaging | 7 | 2008 | 655 | 0.400 |
Why?
|
| Enoxaparin | 1 | 2012 | 57 | 0.400 |
Why?
|
| Cisplatin | 22 | 2011 | 2497 | 0.370 |
Why?
|
| Carcinoma | 10 | 2014 | 2610 | 0.360 |
Why?
|
| Medical Oncology | 7 | 2013 | 1465 | 0.360 |
Why?
|
| Gynecology | 5 | 2013 | 235 | 0.350 |
Why?
|
| Therapies, Investigational | 1 | 2010 | 60 | 0.340 |
Why?
|
| Quality Improvement | 4 | 2019 | 914 | 0.320 |
Why?
|
| Aged, 80 and over | 39 | 2020 | 31050 | 0.300 |
Why?
|
| False Negative Reactions | 4 | 2013 | 291 | 0.300 |
Why?
|
| Mixed Tumor, Mesodermal | 1 | 2007 | 1 | 0.290 |
Why?
|
| Carcinoma, Adenosquamous | 7 | 2017 | 107 | 0.290 |
Why?
|
| Intraoperative Care | 4 | 2006 | 274 | 0.280 |
Why?
|
| Neoplasms, Glandular and Epithelial | 6 | 2012 | 517 | 0.280 |
Why?
|
| Coloring Agents | 7 | 2017 | 233 | 0.270 |
Why?
|
| Surgical Wound Infection | 4 | 2019 | 496 | 0.260 |
Why?
|
| Hemostasis, Surgical | 1 | 2006 | 55 | 0.260 |
Why?
|
| Electrocoagulation | 1 | 2006 | 67 | 0.260 |
Why?
|
| Adenocarcinoma, Clear Cell | 5 | 2017 | 176 | 0.250 |
Why?
|
| Topotecan | 5 | 2020 | 248 | 0.250 |
Why?
|
| Adenocarcinoma | 18 | 2017 | 7916 | 0.240 |
Why?
|
| Prospective Studies | 22 | 2021 | 13424 | 0.240 |
Why?
|
| Radiation Injuries | 7 | 2011 | 1471 | 0.240 |
Why?
|
| Vagina | 2 | 2005 | 331 | 0.240 |
Why?
|
| Deoxycytidine | 2 | 2010 | 1389 | 0.230 |
Why?
|
| Surgical Flaps | 5 | 2005 | 894 | 0.220 |
Why?
|
| Antimetabolites, Antineoplastic | 3 | 2010 | 1347 | 0.220 |
Why?
|
| CA-125 Antigen | 3 | 2016 | 229 | 0.220 |
Why?
|
| Lymphatic Irradiation | 1 | 2003 | 139 | 0.220 |
Why?
|
| Topoisomerase I Inhibitors | 2 | 2020 | 73 | 0.220 |
Why?
|
| Radiopharmaceuticals | 6 | 2017 | 1341 | 0.210 |
Why?
|
| Leiomyosarcoma | 2 | 2016 | 253 | 0.210 |
Why?
|
| Disease-Free Survival | 20 | 2016 | 10265 | 0.210 |
Why?
|
| Retrospective Studies | 44 | 2020 | 39902 | 0.200 |
Why?
|
| Blood Transfusion | 3 | 2019 | 581 | 0.200 |
Why?
|
| Patient Education as Topic | 2 | 2015 | 745 | 0.190 |
Why?
|
| Cystadenocarcinoma, Serous | 5 | 2012 | 499 | 0.190 |
Why?
|
| Antineoplastic Agents, Phytogenic | 6 | 2003 | 894 | 0.190 |
Why?
|
| Sirolimus | 3 | 2015 | 831 | 0.190 |
Why?
|
| Blood Loss, Surgical | 3 | 2019 | 295 | 0.180 |
Why?
|
| Patient Safety | 2 | 2019 | 613 | 0.180 |
Why?
|
| Brachytherapy | 7 | 2012 | 1005 | 0.180 |
Why?
|
| Surgical Equipment | 1 | 2019 | 17 | 0.170 |
Why?
|
| Sensitivity and Specificity | 7 | 2017 | 5171 | 0.170 |
Why?
|
| Reference Standards | 1 | 2021 | 368 | 0.170 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2004 | 841 | 0.170 |
Why?
|
| Terminal Care | 1 | 2004 | 467 | 0.160 |
Why?
|
| Clinical Trials as Topic | 7 | 2016 | 3846 | 0.160 |
Why?
|
| Carcinoma, Endometrioid | 2 | 2017 | 327 | 0.160 |
Why?
|
| Carboplatin | 8 | 2010 | 880 | 0.160 |
Why?
|
| Antineoplastic Agents | 15 | 2015 | 14623 | 0.160 |
Why?
|
| Diffusion of Innovation | 1 | 2019 | 142 | 0.160 |
Why?
|
| Combined Modality Therapy | 17 | 2009 | 9040 | 0.160 |
Why?
|
| Drug Administration Schedule | 12 | 2020 | 3531 | 0.160 |
Why?
|
| Melanoma | 5 | 2016 | 5595 | 0.150 |
Why?
|
| Anticoagulants | 2 | 2015 | 775 | 0.150 |
Why?
|
| Attitude of Health Personnel | 1 | 2004 | 901 | 0.150 |
Why?
|
| Predictive Value of Tests | 6 | 2017 | 4965 | 0.150 |
Why?
|
| Radiation Dosage | 2 | 2021 | 1042 | 0.150 |
Why?
|
| Postoperative Complications | 11 | 2019 | 5682 | 0.150 |
Why?
|
| Triazoles | 2 | 2015 | 627 | 0.140 |
Why?
|
| Patient Care | 1 | 1998 | 148 | 0.140 |
Why?
|
| Intestinal Fistula | 2 | 1995 | 48 | 0.140 |
Why?
|
| Nitriles | 2 | 2015 | 939 | 0.140 |
Why?
|
| Dietary Fiber | 1 | 1997 | 127 | 0.140 |
Why?
|
| Treatment Outcome | 29 | 2021 | 33774 | 0.140 |
Why?
|
| Adaptation, Psychological | 3 | 2014 | 787 | 0.140 |
Why?
|
| Camptothecin | 4 | 2003 | 540 | 0.140 |
Why?
|
| Drug Resistance, Neoplasm | 11 | 2020 | 5409 | 0.140 |
Why?
|
| Quality of Health Care | 2 | 2016 | 619 | 0.140 |
Why?
|
| Incidence | 8 | 2016 | 5829 | 0.140 |
Why?
|
| Proportional Hazards Models | 12 | 2016 | 5102 | 0.140 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2017 | 107 | 0.130 |
Why?
|
| Constipation | 1 | 1997 | 187 | 0.130 |
Why?
|
| Robotics | 2 | 2011 | 365 | 0.130 |
Why?
|
| Catheter-Related Infections | 1 | 2019 | 274 | 0.130 |
Why?
|
| Carcinosarcoma | 1 | 2017 | 146 | 0.130 |
Why?
|
| Hysterectomy, Vaginal | 2 | 2007 | 35 | 0.130 |
Why?
|
| Arterial Occlusive Diseases | 1 | 1996 | 149 | 0.130 |
Why?
|
| Patient Care Team | 2 | 2015 | 823 | 0.130 |
Why?
|
| Taxoids | 7 | 2012 | 1015 | 0.130 |
Why?
|
| Length of Stay | 4 | 2012 | 2008 | 0.130 |
Why?
|
| Appointments and Schedules | 1 | 2015 | 96 | 0.120 |
Why?
|
| Scientific Misconduct | 1 | 1994 | 20 | 0.120 |
Why?
|
| Follow-Up Studies | 22 | 2016 | 15231 | 0.120 |
Why?
|
| Urinary Tract Infections | 1 | 2019 | 345 | 0.120 |
Why?
|
| Mind-Body Therapies | 1 | 2014 | 29 | 0.120 |
Why?
|
| Cross Infection | 1 | 2019 | 550 | 0.120 |
Why?
|
| Physician-Patient Relations | 2 | 2004 | 737 | 0.120 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2016 | 216 | 0.120 |
Why?
|
| Young Adult | 10 | 2017 | 22260 | 0.120 |
Why?
|
| Guideline Adherence | 2 | 2019 | 632 | 0.120 |
Why?
|
| Survival Analysis | 15 | 2016 | 9294 | 0.120 |
Why?
|
| Urinary Bladder Fistula | 1 | 1994 | 14 | 0.120 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2016 | 275 | 0.120 |
Why?
|
| Pilot Projects | 5 | 2007 | 2849 | 0.110 |
Why?
|
| Laparotomy | 2 | 2012 | 235 | 0.110 |
Why?
|
| Cystitis | 1 | 1994 | 109 | 0.110 |
Why?
|
| Spirituality | 1 | 2014 | 129 | 0.110 |
Why?
|
| Colostomy | 2 | 2008 | 80 | 0.110 |
Why?
|
| Hospitals, Special | 1 | 2013 | 26 | 0.110 |
Why?
|
| Sarcoma | 2 | 1996 | 1839 | 0.110 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 2 | 2017 | 113 | 0.110 |
Why?
|
| Myositis | 1 | 1994 | 87 | 0.110 |
Why?
|
| Radiotherapy | 8 | 2007 | 1857 | 0.110 |
Why?
|
| Erythrocyte Transfusion | 1 | 2014 | 206 | 0.110 |
Why?
|
| Adolescent | 16 | 2016 | 32777 | 0.100 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2013 | 1260 | 0.100 |
Why?
|
| Algorithms | 4 | 2020 | 3900 | 0.100 |
Why?
|
| Paclitaxel | 8 | 2010 | 2101 | 0.100 |
Why?
|
| Health Care Costs | 2 | 2019 | 699 | 0.100 |
Why?
|
| Genital Diseases, Female | 1 | 2012 | 60 | 0.100 |
Why?
|
| Mesna | 3 | 2007 | 67 | 0.100 |
Why?
|
| Survival Rate | 17 | 2016 | 12542 | 0.100 |
Why?
|
| Drainage | 1 | 1994 | 463 | 0.100 |
Why?
|
| Amifostine | 1 | 2011 | 99 | 0.090 |
Why?
|
| Doxorubicin | 5 | 2012 | 3145 | 0.090 |
Why?
|
| Risk Factors | 13 | 2019 | 17904 | 0.090 |
Why?
|
| Professional Staff Committees | 2 | 2001 | 30 | 0.090 |
Why?
|
| Streptococcal Infections | 1 | 1994 | 317 | 0.090 |
Why?
|
| Radiation-Protective Agents | 1 | 2011 | 129 | 0.090 |
Why?
|
| Infusions, Intravenous | 9 | 2015 | 1437 | 0.090 |
Why?
|
| Ifosfamide | 3 | 2007 | 358 | 0.090 |
Why?
|
| Cost-Benefit Analysis | 2 | 2012 | 965 | 0.090 |
Why?
|
| Carcinoma, Papillary | 2 | 2003 | 566 | 0.090 |
Why?
|
| Workload | 1 | 2012 | 195 | 0.090 |
Why?
|
| Health Expenditures | 1 | 2012 | 202 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2016 | 7785 | 0.090 |
Why?
|
| Piperazines | 2 | 2012 | 2145 | 0.090 |
Why?
|
| Mixed Tumor, Mullerian | 2 | 2003 | 37 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2010 | 5071 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 3 | 2019 | 2401 | 0.090 |
Why?
|
| Hemorrhage | 1 | 1994 | 727 | 0.090 |
Why?
|
| Insurance Coverage | 1 | 2012 | 275 | 0.090 |
Why?
|
| Quality Indicators, Health Care | 1 | 2013 | 354 | 0.080 |
Why?
|
| Feasibility Studies | 4 | 2008 | 2364 | 0.080 |
Why?
|
| Attitude to Death | 2 | 2004 | 102 | 0.080 |
Why?
|
| Marital Status | 1 | 2009 | 92 | 0.080 |
Why?
|
| Sexual Behavior | 2 | 2005 | 313 | 0.080 |
Why?
|
| Immunohistochemistry | 7 | 2015 | 7665 | 0.080 |
Why?
|
| Prognosis | 13 | 2016 | 22509 | 0.080 |
Why?
|
| Fluorouracil | 5 | 2007 | 1990 | 0.080 |
Why?
|
| Magnesium Deficiency | 1 | 2009 | 21 | 0.080 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2020 | 4962 | 0.080 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2009 | 334 | 0.080 |
Why?
|
| Cystadenocarcinoma, Papillary | 2 | 2001 | 82 | 0.080 |
Why?
|
| Retroperitoneal Space | 2 | 2006 | 156 | 0.070 |
Why?
|
| Injections, Intraperitoneal | 3 | 2015 | 209 | 0.070 |
Why?
|
| Glutathione | 1 | 2010 | 375 | 0.070 |
Why?
|
| Burnout, Professional | 1 | 2011 | 224 | 0.070 |
Why?
|
| Data Collection | 2 | 2013 | 608 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 4 | 2016 | 4001 | 0.070 |
Why?
|
| Disease Progression | 6 | 2010 | 6868 | 0.070 |
Why?
|
| Quality Assurance, Health Care | 1 | 2012 | 596 | 0.070 |
Why?
|
| Technetium Compounds | 1 | 2006 | 12 | 0.070 |
Why?
|
| Hysteroscopy | 1 | 2007 | 47 | 0.070 |
Why?
|
| Cohort Studies | 6 | 2016 | 9479 | 0.070 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 1994 | 1689 | 0.070 |
Why?
|
| Salvage Therapy | 5 | 2006 | 2123 | 0.070 |
Why?
|
| Inguinal Canal | 2 | 1997 | 64 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2014 | 3409 | 0.070 |
Why?
|
| Pyrimidines | 2 | 2012 | 3671 | 0.070 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2010 | 1302 | 0.070 |
Why?
|
| Texas | 7 | 2016 | 6450 | 0.070 |
Why?
|
| Appendix | 1 | 2006 | 45 | 0.070 |
Why?
|
| Organoplatinum Compounds | 4 | 2012 | 704 | 0.070 |
Why?
|
| Indocyanine Green | 2 | 2017 | 125 | 0.070 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2012 | 1269 | 0.070 |
Why?
|
| Polyethylene Glycols | 1 | 2010 | 654 | 0.070 |
Why?
|
| United States | 5 | 2016 | 15868 | 0.060 |
Why?
|
| Hospitalization | 1 | 2015 | 2171 | 0.060 |
Why?
|
| Platinum Compounds | 3 | 2010 | 129 | 0.060 |
Why?
|
| Appendectomy | 1 | 2006 | 132 | 0.060 |
Why?
|
| Breast Neoplasms | 3 | 2012 | 16216 | 0.060 |
Why?
|
| Tumor Burden | 1 | 2011 | 2034 | 0.060 |
Why?
|
| Hot Temperature | 1 | 2006 | 289 | 0.060 |
Why?
|
| Lymphatic Vessels | 1 | 2006 | 138 | 0.060 |
Why?
|
| Neoplasm, Residual | 2 | 2010 | 1754 | 0.060 |
Why?
|
| Neoplasm Metastasis | 4 | 2016 | 5315 | 0.060 |
Why?
|
| Splenic Neoplasms | 1 | 2005 | 124 | 0.060 |
Why?
|
| Research Design | 3 | 2001 | 1571 | 0.060 |
Why?
|
| Cytoreduction Surgical Procedures | 2 | 2020 | 510 | 0.060 |
Why?
|
| Progestins | 1 | 2004 | 92 | 0.060 |
Why?
|
| Rectus Abdominis | 1 | 2005 | 92 | 0.060 |
Why?
|
| Vacuum | 1 | 2004 | 43 | 0.060 |
Why?
|
| Neoplasms | 3 | 2011 | 15933 | 0.060 |
Why?
|
| Uterus | 1 | 2009 | 798 | 0.060 |
Why?
|
| Bevacizumab | 3 | 2014 | 967 | 0.060 |
Why?
|
| Capecitabine | 1 | 2005 | 390 | 0.060 |
Why?
|
| Bone Marrow Transplantation | 2 | 2004 | 1757 | 0.060 |
Why?
|
| Azacitidine | 1 | 2010 | 1218 | 0.060 |
Why?
|
| Graft vs Tumor Effect | 1 | 2004 | 143 | 0.060 |
Why?
|
| Urethral Neoplasms | 1 | 2004 | 62 | 0.060 |
Why?
|
| Neutropenia | 4 | 2014 | 1006 | 0.060 |
Why?
|
| History, 20th Century | 2 | 2000 | 544 | 0.050 |
Why?
|
| Body Mass Index | 2 | 2012 | 2238 | 0.050 |
Why?
|
| Time Factors | 7 | 2021 | 13024 | 0.050 |
Why?
|
| Quality of Life | 4 | 2016 | 4778 | 0.050 |
Why?
|
| Age Factors | 3 | 2012 | 5468 | 0.050 |
Why?
|
| Hemangiosarcoma | 1 | 2005 | 238 | 0.050 |
Why?
|
| Health Care Surveys | 1 | 2004 | 418 | 0.050 |
Why?
|
| Patient Selection | 2 | 2008 | 2026 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 2 | 2017 | 4048 | 0.050 |
Why?
|
| Truth Disclosure | 1 | 2004 | 179 | 0.050 |
Why?
|
| Choriocarcinoma | 1 | 2002 | 49 | 0.050 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 2 | 2001 | 271 | 0.050 |
Why?
|
| Etoposide | 3 | 2000 | 907 | 0.050 |
Why?
|
| Fertility | 1 | 2004 | 336 | 0.050 |
Why?
|
| Cyclophosphamide | 5 | 2009 | 3245 | 0.050 |
Why?
|
| Colon, Sigmoid | 1 | 2001 | 42 | 0.050 |
Why?
|
| Receptors, Progesterone | 3 | 2015 | 1604 | 0.050 |
Why?
|
| Neoplasm Micrometastasis | 1 | 2021 | 50 | 0.050 |
Why?
|
| Granulosa Cell Tumor | 2 | 1999 | 81 | 0.050 |
Why?
|
| Biomarkers, Tumor | 4 | 2015 | 10709 | 0.050 |
Why?
|
| Trophoblasts | 1 | 2002 | 152 | 0.050 |
Why?
|
| Logistic Models | 3 | 2012 | 3448 | 0.040 |
Why?
|
| Intestinal Perforation | 1 | 2001 | 108 | 0.040 |
Why?
|
| Multivariate Analysis | 5 | 2012 | 4329 | 0.040 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2000 | 770 | 0.040 |
Why?
|
| Melphalan | 4 | 2007 | 879 | 0.040 |
Why?
|
| Receptors, Estrogen | 3 | 2015 | 2170 | 0.040 |
Why?
|
| Lymphatic System | 1 | 2000 | 55 | 0.040 |
Why?
|
| Survivors | 1 | 2005 | 1023 | 0.040 |
Why?
|
| Genes, p53 | 1 | 2004 | 1140 | 0.040 |
Why?
|
| Preoperative Care | 1 | 2006 | 1567 | 0.040 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2003 | 481 | 0.040 |
Why?
|
| History, 19th Century | 1 | 2000 | 145 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2004 | 7045 | 0.040 |
Why?
|
| Vulva | 2 | 2000 | 38 | 0.040 |
Why?
|
| Colorectal Neoplasms | 2 | 2012 | 3707 | 0.040 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2019 | 32 | 0.040 |
Why?
|
| Abdominal Neoplasms | 1 | 2001 | 251 | 0.040 |
Why?
|
| Wound Healing | 1 | 2004 | 768 | 0.040 |
Why?
|
| Thrombocytopenia | 3 | 2014 | 870 | 0.040 |
Why?
|
| Vidarabine | 1 | 2004 | 1384 | 0.040 |
Why?
|
| Positron-Emission Tomography | 3 | 2013 | 2197 | 0.040 |
Why?
|
| Cost Savings | 1 | 2019 | 123 | 0.040 |
Why?
|
| Perioperative Period | 1 | 2019 | 149 | 0.040 |
Why?
|
| Education, Medical, Graduate | 1 | 2004 | 705 | 0.040 |
Why?
|
| Life Tables | 2 | 1994 | 120 | 0.040 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 2 | 2006 | 347 | 0.040 |
Why?
|
| Defecation | 1 | 1997 | 57 | 0.040 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2004 | 743 | 0.040 |
Why?
|
| Infusions, Intra-Arterial | 2 | 1995 | 175 | 0.040 |
Why?
|
| Surveys and Questionnaires | 3 | 2005 | 5928 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2016 | 2655 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2019 | 478 | 0.040 |
Why?
|
| Neoplasms, Second Primary | 1 | 2005 | 1388 | 0.040 |
Why?
|
| Vinblastine | 1 | 1998 | 462 | 0.040 |
Why?
|
| Government Agencies | 1 | 2016 | 24 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2016 | 6257 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2009 | 4481 | 0.030 |
Why?
|
| Aorta | 3 | 2013 | 670 | 0.030 |
Why?
|
| Cancer Care Facilities | 2 | 2002 | 907 | 0.030 |
Why?
|
| Genetic Therapy | 1 | 2004 | 1716 | 0.030 |
Why?
|
| Lung Neoplasms | 3 | 2004 | 12033 | 0.030 |
Why?
|
| Mitotic Index | 1 | 2016 | 162 | 0.030 |
Why?
|
| Sex Cord-Gonadal Stromal Tumors | 1 | 1996 | 38 | 0.030 |
Why?
|
| Urinary Diversion | 1 | 1996 | 86 | 0.030 |
Why?
|
| Critical Pathways | 1 | 1997 | 160 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 2003 | 1174 | 0.030 |
Why?
|
| Anxiety | 2 | 2014 | 1240 | 0.030 |
Why?
|
| Floxuridine | 1 | 1995 | 41 | 0.030 |
Why?
|
| Radiation Oncology | 1 | 2001 | 558 | 0.030 |
Why?
|
| Reference Values | 2 | 2010 | 1134 | 0.030 |
Why?
|
| Intraoperative Period | 1 | 1995 | 251 | 0.030 |
Why?
|
| Fistula | 1 | 1996 | 77 | 0.030 |
Why?
|
| Colonic Diseases | 1 | 1996 | 70 | 0.030 |
Why?
|
| Radiology | 1 | 2020 | 426 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2001 | 3604 | 0.030 |
Why?
|
| Soft Tissue Injuries | 1 | 1995 | 48 | 0.030 |
Why?
|
| Transplantation Conditioning | 1 | 2004 | 2374 | 0.030 |
Why?
|
| Trophoblastic Neoplasms | 1 | 1994 | 23 | 0.030 |
Why?
|
| Imatinib Mesylate | 2 | 2012 | 1691 | 0.030 |
Why?
|
| Injections, Intradermal | 1 | 1994 | 51 | 0.030 |
Why?
|
| Buttocks | 1 | 1994 | 14 | 0.030 |
Why?
|
| Perineum | 1 | 1995 | 115 | 0.030 |
Why?
|
| Surgeons | 1 | 2020 | 494 | 0.030 |
Why?
|
| Aspartate Aminotransferases | 1 | 2014 | 147 | 0.030 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2000 | 1067 | 0.030 |
Why?
|
| Rectal Neoplasms | 2 | 2008 | 1240 | 0.030 |
Why?
|
| Patient Satisfaction | 2 | 2015 | 920 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2009 | 2271 | 0.030 |
Why?
|
| Ureteral Obstruction | 1 | 1995 | 146 | 0.030 |
Why?
|
| Benzamides | 2 | 2012 | 1879 | 0.030 |
Why?
|
| Mandatory Reporting | 1 | 2013 | 27 | 0.030 |
Why?
|
| Mucositis | 1 | 2014 | 149 | 0.030 |
Why?
|
| Chemoradiotherapy | 2 | 2013 | 2027 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 681 | 0.030 |
Why?
|
| Recurrence | 3 | 2010 | 4881 | 0.030 |
Why?
|
| Fee-for-Service Plans | 1 | 2013 | 43 | 0.030 |
Why?
|
| Male | 6 | 2016 | 128533 | 0.030 |
Why?
|
| Smoking | 1 | 2002 | 2555 | 0.030 |
Why?
|
| Lymphoscintigraphy | 1 | 2012 | 35 | 0.030 |
Why?
|
| Colon | 1 | 1996 | 659 | 0.030 |
Why?
|
| Carcinoma in Situ | 1 | 1996 | 489 | 0.030 |
Why?
|
| Palliative Care | 2 | 2002 | 2178 | 0.030 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 1992 | 119 | 0.030 |
Why?
|
| Everolimus | 1 | 2015 | 436 | 0.030 |
Why?
|
| Insurance, Health | 1 | 1994 | 261 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2004 | 311 | 0.030 |
Why?
|
| Therapeutic Irrigation | 1 | 1992 | 92 | 0.030 |
Why?
|
| Psychotherapy | 1 | 2014 | 250 | 0.030 |
Why?
|
| Phosphorylcholine | 1 | 2012 | 56 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 1994 | 929 | 0.020 |
Why?
|
| Population Surveillance | 1 | 1995 | 647 | 0.020 |
Why?
|
| Blood Volume | 1 | 2012 | 107 | 0.020 |
Why?
|
| ErbB Receptors | 1 | 2020 | 2376 | 0.020 |
Why?
|
| Endometriosis | 1 | 2015 | 231 | 0.020 |
Why?
|
| Ultrasonography | 2 | 2003 | 1933 | 0.020 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2013 | 107 | 0.020 |
Why?
|
| Reproducibility of Results | 2 | 2009 | 6195 | 0.020 |
Why?
|
| Vena Cava, Inferior | 1 | 2013 | 194 | 0.020 |
Why?
|
| Hypercholesterolemia | 1 | 2014 | 263 | 0.020 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2017 | 880 | 0.020 |
Why?
|
| Internal-External Control | 1 | 2011 | 108 | 0.020 |
Why?
|
| Organizational Objectives | 2 | 2001 | 66 | 0.020 |
Why?
|
| beta Catenin | 1 | 2015 | 683 | 0.020 |
Why?
|
| Eponyms | 1 | 2000 | 2 | 0.020 |
Why?
|
| Perioperative Care | 1 | 2014 | 447 | 0.020 |
Why?
|
| Ovariectomy | 2 | 2006 | 371 | 0.020 |
Why?
|
| Postoperative Care | 2 | 2010 | 730 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2015 | 680 | 0.020 |
Why?
|
| Sacrococcygeal Region | 1 | 2000 | 44 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2015 | 1061 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 986 | 0.020 |
Why?
|
| Robotic Surgical Procedures | 1 | 2017 | 535 | 0.020 |
Why?
|
| Actuarial Analysis | 2 | 2002 | 170 | 0.020 |
Why?
|
| Intraoperative Complications | 1 | 2012 | 288 | 0.020 |
Why?
|
| Recombinant Proteins | 2 | 2009 | 3029 | 0.020 |
Why?
|
| Kidney Transplantation | 1 | 1995 | 761 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2016 | 2251 | 0.020 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2009 | 88 | 0.020 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2012 | 742 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2012 | 1322 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2015 | 2357 | 0.020 |
Why?
|
| Multimodal Imaging | 1 | 2013 | 550 | 0.020 |
Why?
|
| ROC Curve | 1 | 2012 | 1250 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2004 | 751 | 0.020 |
Why?
|
| Magnesium | 1 | 2009 | 170 | 0.020 |
Why?
|
| Probability | 2 | 2004 | 886 | 0.020 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 1995 | 999 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2015 | 1432 | 0.020 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2011 | 509 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2016 | 1340 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2015 | 1564 | 0.020 |
Why?
|
| Anemia | 2 | 2006 | 728 | 0.020 |
Why?
|
| Analysis of Variance | 2 | 2005 | 2320 | 0.020 |
Why?
|
| Contraceptive Devices, Female | 1 | 2007 | 6 | 0.020 |
Why?
|
| Social Class | 1 | 2009 | 324 | 0.020 |
Why?
|
| Mass Screening | 1 | 1996 | 1554 | 0.020 |
Why?
|
| Fatigue | 1 | 2014 | 1278 | 0.020 |
Why?
|
| Equipment Safety | 1 | 2007 | 64 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2012 | 625 | 0.020 |
Why?
|
| Radiotherapy, Conformal | 1 | 2013 | 898 | 0.020 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2009 | 425 | 0.020 |
Why?
|
| Transplantation, Autologous | 2 | 2004 | 2067 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2012 | 1823 | 0.020 |
Why?
|
| Leukopenia | 1 | 2007 | 152 | 0.020 |
Why?
|
| Elective Surgical Procedures | 1 | 2008 | 249 | 0.020 |
Why?
|
| Pelvic Neoplasms | 2 | 2001 | 199 | 0.020 |
Why?
|
| Decision Making | 1 | 1994 | 1253 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 2 | 2003 | 1189 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 2004 | 5867 | 0.020 |
Why?
|
| Cystadenocarcinoma, Mucinous | 1 | 2006 | 22 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2010 | 1430 | 0.020 |
Why?
|
| Agranulocytosis | 1 | 2006 | 83 | 0.020 |
Why?
|
| Drug Administration Routes | 1 | 2006 | 61 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 2400 | 0.020 |
Why?
|
| Proteasome Inhibitors | 1 | 2007 | 235 | 0.020 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2009 | 442 | 0.020 |
Why?
|
| Boronic Acids | 1 | 2007 | 354 | 0.020 |
Why?
|
| Bortezomib | 1 | 2007 | 549 | 0.020 |
Why?
|
| Triazines | 1 | 2006 | 122 | 0.020 |
Why?
|
| Diagnosis, Differential | 2 | 2005 | 4832 | 0.020 |
Why?
|
| Reoperation | 2 | 2001 | 1392 | 0.020 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2007 | 368 | 0.020 |
Why?
|
| Medical Records | 1 | 2006 | 442 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2009 | 1180 | 0.010 |
Why?
|
| Depression | 1 | 2014 | 1733 | 0.010 |
Why?
|
| Pyrazines | 1 | 2007 | 510 | 0.010 |
Why?
|
| Child | 4 | 2012 | 30578 | 0.010 |
Why?
|
| Anus Neoplasms | 1 | 2008 | 414 | 0.010 |
Why?
|
| Hypertension | 1 | 2014 | 1592 | 0.010 |
Why?
|
| Occlusive Dressings | 1 | 2004 | 14 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 1994 | 4379 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 2346 | 0.010 |
Why?
|
| Lymphography | 1 | 2003 | 50 | 0.010 |
Why?
|
| Equipment Design | 1 | 2007 | 1209 | 0.010 |
Why?
|
| Adenoviruses, Human | 1 | 2004 | 191 | 0.010 |
Why?
|
| Aorta, Abdominal | 1 | 2004 | 151 | 0.010 |
Why?
|
| Risk Assessment | 2 | 2007 | 6772 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2016 | 5231 | 0.010 |
Why?
|
| Antilymphocyte Serum | 1 | 2004 | 237 | 0.010 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2003 | 153 | 0.010 |
Why?
|
| Tomography, Emission-Computed | 1 | 2003 | 334 | 0.010 |
Why?
|
| Urinary Bladder Diseases | 1 | 2002 | 53 | 0.010 |
Why?
|
| Case-Control Studies | 2 | 2005 | 6239 | 0.010 |
Why?
|
| Intestinal Diseases | 1 | 2002 | 125 | 0.010 |
Why?
|
| Surgical Procedures, Operative | 1 | 2004 | 359 | 0.010 |
Why?
|
| Sentinel Surveillance | 1 | 2000 | 35 | 0.010 |
Why?
|
| Postmenopause | 1 | 2002 | 377 | 0.010 |
Why?
|
| DNA Methylation | 1 | 2010 | 2767 | 0.010 |
Why?
|
| Filgrastim | 1 | 2000 | 194 | 0.010 |
Why?
|
| Research Support as Topic | 1 | 2001 | 120 | 0.010 |
Why?
|
| Remission Induction | 2 | 1998 | 3657 | 0.010 |
Why?
|
| Blood Component Removal | 1 | 2000 | 119 | 0.010 |
Why?
|
| Antigens, CD20 | 1 | 2000 | 207 | 0.010 |
Why?
|
| Prostate-Specific Antigen | 1 | 2004 | 1029 | 0.010 |
Why?
|
| CD3 Complex | 1 | 2000 | 320 | 0.010 |
Why?
|
| Liposomes | 1 | 2001 | 704 | 0.010 |
Why?
|
| Bridged-Ring Compounds | 1 | 2000 | 190 | 0.010 |
Why?
|
| Drug Resistance, Multiple | 1 | 2000 | 221 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2015 | 9045 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2007 | 4019 | 0.010 |
Why?
|
| Sezary Syndrome | 1 | 2000 | 171 | 0.010 |
Why?
|
| Forecasting | 1 | 2001 | 702 | 0.010 |
Why?
|
| Mycosis Fungoides | 1 | 2000 | 341 | 0.010 |
Why?
|
| Managed Care Programs | 1 | 1997 | 83 | 0.010 |
Why?
|
| Inpatients | 1 | 2002 | 686 | 0.010 |
Why?
|
| Sertoli-Leydig Cell Tumor | 1 | 1996 | 20 | 0.010 |
Why?
|
| Costs and Cost Analysis | 1 | 1997 | 310 | 0.010 |
Why?
|
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 1995 | 24 | 0.010 |
Why?
|
| Rectal Diseases | 1 | 1995 | 57 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1995 | 452 | 0.010 |
Why?
|
| Urologic Diseases | 1 | 1995 | 83 | 0.010 |
Why?
|
| Bleomycin | 1 | 1996 | 482 | 0.010 |
Why?
|
| Parity | 1 | 1994 | 136 | 0.010 |
Why?
|
| Fallopian Tubes | 1 | 1995 | 129 | 0.010 |
Why?
|
| Ureter | 1 | 1996 | 219 | 0.010 |
Why?
|
| Administration, Oral | 1 | 1998 | 1610 | 0.010 |
Why?
|
| Program Evaluation | 1 | 1997 | 603 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2001 | 1875 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 1995 | 824 | 0.010 |
Why?
|
| Receptor, ErbB-2 | 1 | 2003 | 2651 | 0.010 |
Why?
|
| Lymphoma, B-Cell | 1 | 2000 | 929 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1993 | 591 | 0.010 |
Why?
|
| Intestinal Obstruction | 1 | 1995 | 223 | 0.010 |
Why?
|
| Catheters, Indwelling | 1 | 1995 | 383 | 0.010 |
Why?
|
| Radiation Tolerance | 1 | 1995 | 639 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 1996 | 2058 | 0.010 |
Why?
|
| Gastrointestinal Diseases | 1 | 1995 | 608 | 0.010 |
Why?
|
| Stents | 1 | 1996 | 999 | 0.010 |
Why?
|
| Skin | 1 | 1995 | 1274 | 0.010 |
Why?
|
| Biopsy | 1 | 1996 | 3485 | 0.000 |
Why?
|
| Brain Neoplasms | 1 | 2004 | 4958 | 0.000 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2003 | 7896 | 0.000 |
Why?
|
| Liver Neoplasms | 1 | 2004 | 4821 | 0.000 |
Why?
|
| Skin Neoplasms | 1 | 2000 | 4895 | 0.000 |
Why?
|
| Pregnancy | 1 | 1994 | 8131 | 0.000 |
Why?
|